EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG

 

 

Ad-hoc RELEASE

Announcement according to Article 17 European Market Abuse Regulation (MAR)

 

Change of the Chief Executive Officer (CEO) of Biotest AG

 Dreieich, 28 May 2025. The Supervisory Board of Biotest AG today decided on a change of Chief Executive Officer (CEO).

Dr Jörg Schüttrumpf was appointed today as a member of the Management Board of Biotest AG for three years with immediate effect. He also assumes the function of CEO of Biotest AG with immediate effect. He succeeds Peter Janssen, former CEO of Biotest AG, who was dismissed today as member of the Management Board and CEO of Biotest AG with immediate effect by mutual agreement.

The Supervisory Board would like to thank Mr Janssen for his commitment and cooperation over the past years. Dr Schüttrumpf was already a member of the Management Board of Biotest AG from 1 January 2022 to 31 August 2024. Since his departure, he has worked for Grifols S.A., the main shareholder of Biotest AG.

 

Biotest Aktiengesellschaft
Board of Management

 

Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com

 

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,500 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been part of the Grifols Group, Barcelona, Spain (www.grifols.com).

 

 

IR contact

Dr. Monika Baumann (Buttkereit)

phone: +49-6103-801-4406
email: ir@biotest.com

 

PR contact

Dirk Neumüller

phone: +49-6103-801-269
email: pr@biotest.com

 

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

 

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate